产品: PPAR alpha 抗体
货号: AF5301
描述: Rabbit polyclonal antibody to PPAR alpha
应用: WB IHC IF/ICC
反应: Human, Mouse, Rat
预测: Bovine, Horse, Sheep, Rabbit, Dog, Xenopus
分子量: 52 kDa; 52kD(Calculated).
蛋白号: Q07869
RRID: AB_2837786

浏览相似产品>>

   规格 价格 库存
 50ul RMB¥ 1250 现货
 100ul RMB¥ 2300 现货
 200ul RMB¥ 3000 现货

货期: 当天发货

联系销售

产品描述

来源:
Rabbit
应用:
WB 1:500-1:2000, IHC 1:50-1:200, IF/ICC 1:100-1:500
*The optimal dilutions should be determined by the end user.
*Tips:

WB: 适用于变性蛋白样本的免疫印迹检测. IHC: 适用于组织样本的石蜡(IHC-p)或冰冻(IHC-f)切片样本的免疫组化/荧光检测. IF/ICC: 适用于细胞样本的荧光检测. ELISA(peptide): 适用于抗原肽的ELISA检测.

反应:
Human,Mouse,Rat
预测:
Bovine(100%), Horse(88%), Sheep(100%), Rabbit(100%), Dog(100%), Xenopus(100%)
克隆:
Polyclonal
特异性:
PPAR alpha Antibody detects endogenous levels of total PPAR alpha.
RRID:
AB_2837786
引用格式: Affinity Biosciences Cat# AF5301, RRID:AB_2837786.
偶联:
Unconjugated.
纯化:
The antiserum was purified by peptide affinity chromatography using SulfoLink™ Coupling Resin (Thermo Fisher Scientific).
保存:
Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.
别名:

展开/折叠

hPPAR; MGC2237; MGC2452; NR1C1; Nuclear receptor subfamily 1 group C member 1; OTTHUMP00000197740; OTTHUMP00000197741; Peroxisome proliferative activated receptor alpha; Peroxisome proliferator activated receptor alpha; Peroxisome proliferator-activated receptor alpha; PPAR; PPAR-alpha; ppara; PPARA_HUMAN; PPARalpha;

抗原和靶标

免疫原:
Uniprot:
基因/基因ID:
表达:
Q07869 PPARA_HUMAN:

Skeletal muscle, liver, heart and kidney. Expressed in monocytes (PubMed:28167758).

描述:
Ligand-activated transcription factor. Key regulator of lipid metabolism. Activated by the endogenous ligand 1-palmitoyl-2-oleoyl-sn-glycerol-3-phosphocholine (16:0/18:1-GPC). Activated by oleylethanolamide, a naturally occurring lipid that regulates satiety (By similarity). Receptor for peroxisome proliferators such as hypolipidemic drugs and fatty acids. Regulates the peroxisomal beta-oxidation pathway of fatty acids.
序列:
MVDTESPLCPLSPLEAGDLESPLSEEFLQEMGNIQEISQSIGEDSSGSFGFTEYQYLGSCPGSDGSVITDTLSPASSPSSVTYPVVPGSVDESPSGALNIECRICGDKASGYHYGVHACEGCKGFFRRTIRLKLVYDKCDRSCKIQKKNRNKCQYCRFHKCLSVGMSHNAIRFGRMPRSEKAKLKAEILTCEHDIEDSETADLKSLAKRIYEAYLKNFNMNKVKARVILSGKASNNPPFVIHDMETLCMAEKTLVAKLVANGIQNKEAEVRIFHCCQCTSVETVTELTEFAKAIPGFANLDLNDQVTLLKYGVYEAIFAMLSSVMNKDGMLVAYGNGFITREFLKSLRKPFCDIMEPKFDFAMKFNALELDDSDISLFVAAIICCGDRPGLLNVGHIEKMQEGIVHVLRLHLQSNHPDDIFLFPKLLQKMADLRQLVTEHAQLVQIIKKTESDAALHPLLQEIYRDMY

种属预测

种属预测:

score>80的预测可信度较高,可尝试用于WB检测。*预测模型主要基于免疫原序列比对,结果仅作参考,不作为质保凭据。

Species
Results
Score
Bovine
100
Sheep
100
Dog
100
Xenopus
100
Rabbit
100
Horse
88
Pig
0
Zebrafish
0
Chicken
0
Model Confidence:
High(score>80) Medium(80>score>50) Low(score<50) No confidence

翻译修饰 - Q07869 作为底物

Site PTM Type Enzyme
S6 Phosphorylation
S12 Phosphorylation P28482 (MAPK1) , P27361 (MAPK3)
S21 Phosphorylation P27361 (MAPK3) , P28482 (MAPK1)
S45 Phosphorylation
S179 Phosphorylation P05771-2 (PRKCB) , P17252 (PRKCA)
K185 Sumoylation
S230 Phosphorylation P05771-2 (PRKCB) , P17252 (PRKCA)

研究背景

功能:

Ligand-activated transcription factor. Key regulator of lipid metabolism. Activated by the endogenous ligand 1-palmitoyl-2-oleoyl-sn-glycerol-3-phosphocholine (16:0/18:1-GPC). Activated by oleylethanolamide, a naturally occurring lipid that regulates satiety. Receptor for peroxisome proliferators such as hypolipidemic drugs and fatty acids. Regulates the peroxisomal beta-oxidation pathway of fatty acids. Functions as transcription activator for the ACOX1 and P450 genes. Transactivation activity requires heterodimerization with RXRA and is antagonized by NR2C2. May be required for the propagation of clock information to metabolic pathways regulated by PER2.

细胞定位:

Nucleus.

Extracellular region or secreted Cytosol Plasma membrane Cytoskeleton Lysosome Endosome Peroxisome ER Golgi apparatus Nucleus Mitochondrion Manual annotation Automatic computational assertionSubcellular location
组织特异性:

Skeletal muscle, liver, heart and kidney. Expressed in monocytes.

亚基结构:

Heterodimer; with RXRA. This heterodimerization is required for DNA binding and transactivation activity. Interacts with NCOA3 coactivator. Interacts with CITED2; the interaction stimulates its transcriptional activity. Also interacts with PPARBP in vitro. Interacts with AKAP13, LPIN1, PRDM16 and coactivator NCOA6. Interacts with ASXL1 and ASXL2. Interacts with PER2. Interacts with SIRT1; the interaction seems to be modulated by NAD(+) levels. Interacts with CRY1 and CRY2 (By similarity).

蛋白家族:

Belongs to the nuclear hormone receptor family. NR1 subfamily.

研究领域

· Environmental Information Processing > Signal transduction > cAMP signaling pathway.   (View pathway)

· Human Diseases > Endocrine and metabolic diseases > Insulin resistance.

· Human Diseases > Endocrine and metabolic diseases > Non-alcoholic fatty liver disease (NAFLD).

· Human Diseases > Infectious diseases: Viral > Hepatitis C.

· Organismal Systems > Endocrine system > PPAR signaling pathway.

· Organismal Systems > Endocrine system > Adipocytokine signaling pathway.

· Organismal Systems > Endocrine system > Glucagon signaling pathway.

文献引用

1). Rescuing SERCA2 pump deficiency improves bone mechano-responsiveness in type 2 diabetes by shaping osteocyte calcium dynamics. Nature communications, 2024 (PubMed: 38291059) [IF=16.6]

Application: WB    Species: Mouse    Sample:

Fig. 9 The nuclear transcription factor PPARα mediates T2D-induced specific reduction in the expression of osteocytic SERCA2 pump. a RNA-seq-based KEGG pathway analysis showing the top 10 enriched KEGG pathways. b, c GSEA analysis showing a significant enrichment of signaling events associated with PPARα and PPARDR1_Q2. d The PPARα and p-PPARα protein expression in osteocytes. e Immunohistochemical staining of osteocytic PPARα in diabetic and non-diabetic tibiae. f The SERCA2 expression in osteocytes treated with antagonists of PPARα (MK886 and GW6471), PPARβ/δ (GSK0660 and GSK3787), and PPARγ (T0070907 and GW9662). g The SERCA2 expression in HGHF-exposed osteocytes treated with agonists of PPARα (Fenofibrate and GW7647), PPARβ/δ (GW0742 and GW501516), and PPARγ (rosiglitazone and pioglitazone). h A schematic representation and the relative luciferase activities of three ATP2A2 promotor regions. i The relative luciferase activity assays of Seg#1, Seg#2 and Seg#3. j The relative luciferase activity in HGHF-treated osteocytes with PPARα silencing. k ChIP assays showing the PPARα enrichment on ATP2A2 promotor in normal and HGHF-treated osteocytes. l EMSA assays confirming the binding of PPARα to the ATP2A2 promoter region (−620 to −608 bp). The nuclear extract were incubated with biotin-labeled wild-type (WT-biotin) probe, unlabeled wild-type (WT) probe, and biotin-labeled mutated (Mut-biotin) probe. Red letters indicate substituted nucleotide sequences in the mutated probes (P1: −620 to −608 bp; P2: −1283 to −1277 bp). m, n Intracellular Ca2+ signaling and protein expression of osteocyte-related cytokines in HGHF-treated osteocytes with PPARα overexpression subjected to FSS. o, p Intracellular Ca2+ signaling and the expression of osteocyte-related cytokines in MLO-Y4 cells with lentiviral silencing of PPARα subjected to FSS. Graphs represent mean ± SD (d, f, g, i–k, m, o n = 6 biologically independent replicates; e n = 8 mice per group; l n = 3 independent replicates; n, p: n = 120 cells per group). a P value was obtained by one-tailed hypergeometric test. b, c P values were obtained by one-tailed permutation test. d–h, n, p ***P 

2). Regulatory effects mediated by ulvan oligosaccharide and its zinc complex on lipid metabolism in high-fat diet-fed mice. Carbohydrate Polymers, 2023 (PubMed: 36372481) [IF=11.2]

3). Hepatic NCoR1 deletion exacerbates alcohol-induced liver injury in mice by promoting CCL2-mediated monocyte-derived macrophage infiltration. Acta Pharmacologica Sinica, 2022 (PubMed: 35149852) [IF=8.2]

4). β-patchoulene improves lipid metabolism to alleviate non-alcoholic fatty liver disease via activating AMPK signaling pathway. BIOMEDICINE & PHARMACOTHERAPY, 2021 (PubMed: 33341045) [IF=7.5]

Application: WB    Species: Human    Sample: L02 cell

Fig. 6. β-PAE promotes the expression of hepatic lipid oxidation-related proteins and genes in HFD-fed rats. (A–G) Western blot analysis on the expression of SIRT1, PGC-1α, PPARα, FGF21, CPT-1a and ACOX1; (H–K) The mRNA expression of SIRT1, PPARα, CPT-1a and ACOX1. Data are presented as the mean ± SD (n = 6~8). ##p < 0.01 vs. NC group; *p < 0.05, **p < 0.01 vs. Model group.

5). Effects of polyphenolic maqui (Aristotelia chilensis) extract on the inhibition of NLRP3 inflammasome and activation of mast cells in a mouse model of Crohn's disease-like colitis. Frontiers in immunology, 2024 (PubMed: 38283356) [IF=7.3]

Application: IHC    Species: Mouse    Sample: colon tissue

Figure 6 Impact of Maqui extract rich in anthocyanins on PPAR-α expression in colon tissue from experimental animal model of Crohn’s disease-like colitis. Immuno‐histochemistry analyses for PPAR-α in epithelial cells from colons of each group (n= 6 mice/group): Positive PPAR-α staining in colon epithelium (black arrow) and crypts cells (dashed arrow) in (A) control group, (B) CD group, (C) post-Treatment and (D) pre-Treatment groups. Immuno‐histochemistry analyses for PPAR-α in macrophages cells from colons tissue from 10 representative fields of view for each group: Immune+-PPAR-α staining intensity (black arrow) in (F) control group, (G) CD group, (H) post-Treatment group and (I) pre-Treatment group, (E) Immune positive score (1= 50%) for PPAR−α expression in epithelial cells. (J) Counting cells across 10 fields (400x magnification) for PPAR−α expression in macrophages cells. Values represent mean ± SEM; *Difference at the p < 0.0005 level; Kruskal–Wallis test.

6). D-Mannose Regulates Hepatocyte Lipid Metabolism via PI3K/Akt/mTOR Signaling Pathway and Ameliorates Hepatic Steatosis in Alcoholic Liver Disease. Frontiers in immunology, 2022 (PubMed: 35464439) [IF=7.3]

7). Yogurt-derived Lactobacillus plantarum Q16 alleviated high-fat diet-induced non-alcoholic fatty liver disease in mice. Food Science and Human Wellness, 2022 [IF=7.0]

Application: WB    Species: Mouse    Sample:

Fig. 5. Effects ofL. plantarum Q16 on key proteins involved in hepatic lipid metabolism in HFD-fed obese mice. Data are presented as mean ± SD (n = 6). Different lowercase alphabet letters were significantly different at the level of P < 0.05.

8). Dietary sanguinarine supplementation recovers the decrease in muscle quality and nutrient composition induced by high-fat diets of grass carp (Ctenopharyngodon idella). Animal nutrition (Zhongguo xu mu shou yi xue hui), 2024 (PubMed: 38800733) [IF=6.3]

Application: WB    Species: fish    Sample:

Fig. 5 The effects of different diets on muscle protein synthesis and lipolysis of grass carp. (A) Protein synthesis related gene expression; (B) lipolysis-related gene expression; (C) Western blot analysis of p-AMPK, AMPK, PPARα, TOR, p70S6K, PI3K, and AKT protein expression; (D) relative quantification of p-AMPK, PPARα, TOR, p70S6K, PI3K, and AKT protein expression. The bars indicate the mean ± standard error (SE). Different superscripts denote significant differences (P < 0.05). CON = a control group (containing 4.95% crude fat); HFD = a high fat diet (containing 10.27% crude fat); HFDS = supplementing 1200 μg/kg sanguinarine to HFD.

9). Probiotic Yogurt Alleviates High-Fat Diet-Induced Lipid Accumulation and Insulin Resistance in Mice via the Adiponectin Pathway. JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, 2023 (PubMed: 36695046) [IF=6.1]

10). Downregulation of HMGCS2 mediated AECIIs lipid metabolic alteration promotes pulmonary fibrosis by activating fibroblasts. Respiratory research, 2024 (PubMed: 38658970) [IF=5.8]

加载更多

限制条款

产品的规格、报价、验证数据请以官网为准,官网链接:www.affbiotech.com | www.affbiotech.cn(简体中文)| www.affbiotech.jp(日本語)

产品的数据信息为Affinity所有,未经授权不得收集Affinity官网数据或资料用于商业用途,对抄袭产品数据的行为我们将保留诉诸法律的权利。

产品相关数据会因产品批次、产品检测情况随时调整,如您已订购该产品,请以订购时随货说明书为准,否则请以官网内容为准,官网内容有改动时恕不另行通知。

Affinity保证所销售产品均经过严格质量检测。如您购买的商品在规定时间内出现问题需要售后时,请您在Affinity官方渠道提交售后申请。

产品仅供科学研究使用。不用于诊断和治疗。 

产品未经授权不得转售。

Affinity Biosciences将不会对在使用我们的产品时可能发生的专利侵权或其他侵权行为负责。Affinity Biosciences, Affinity Biosciences标志和所有其他商标所有权归Affinity Biosciences LTD.